We ignite innovation through AI and biomarkers
View our latest news release
Linearis Labs and Linearis Ventures | Our Mission
Through Linearis Labs’ identification of multi-omics disease signatures and through the capital generated via Linearis Labs, we will amplify the innovation cycle of diagnostics, treatment monitoring and AI drug discovery companies.
Linearis Labs | About our work
Linearis Labs is expanding omics testing and discovery capabilities in North America, Europe and Asia.
We work with leaders in both AI and metabolomics to generate quantitative and actionable AI-friendly data as part of their AI pipelines. Some recent work involves omics signatures for COVID-19 and cancer.
Linearis Labs operates from our recently acquired laboratory space in Québec.
What we do | Our disease signature discovery platform
Linearis Labs couples high throughput technology and mass spectrometry to provide metabolomics analysis of blood plasma or serum for diseases including cancer, diabetes and infectious diseases which have significant metabolomics components.
Using an AI pipeline, disease signatures are discovered and can provide staging of several types of metabolomic diseases (cancer, diabetes, infectious diseases), the effectiveness of therapeutic interventions, and the emergence of resistance and side effects of treatments.
What we do | Biobank analysis services
Linearis Labs offers metabolomics profiling services. Services include both targeted and untargeted LC-MS measurements. High throughput procedures are also available to process thousands of samples using laser diode thermal desorption mass spectrometry. The analyses are carried out in a certified environment and are of clinical quality.
The data is made available in an AI-friendly format for machine learning-based analysis. Linearis Labs can also perform data analysis with state-of-the-art machine learning algorithms.
As metabolomics is closer to the phenotype of interest, it is a great advantage for biobanks to acquire metabolomics data (e.g. UK Biobank). Moreover, there is now an expectation that multi-omics analyses will be available for publication and for better interpretation of the diseases under analysis.
The impact across the health continuum
Linearis Ventures | What we do
Linearis Ventures, the responsible AI health fund, is an evergreen fund that provides access to capital and disease signatures in Cancer, AMR and Diabetes to facilitate diagnosis, monitoring treatment and improve drug discovery for our partners.